Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
State Street Corp's Strategic Acquisition of Shares in Ocugen Inc
Ocugen Analyst Ratings
Maxim Group Initiates Ocugen(OCGN.US) With Buy Rating, Announces Target Price $4
Express News | Ocugen Inc : Maxim Group Initiates Coverage With Buy Rating; Target Price $4
Ocugen Advances Promising Pipeline Amid Financial Restraints
Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of FOMC Meeting Minutes
Ocugen Says FDA Lifts Clinical Hold on Diabetic Macular Edema Drug
Express News | Ocugen Inc - to Pursue Additional Indications for Ocu200
Express News | Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for Ocu200 Phase 1 Clinical Trial
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
Ocugen's (OCGN) Stock Surges 195% on Promising Gene Therapy Treatment
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
Sector Update: Health Care Stocks Steady Premarket Wednesday
Exchange-Traded Funds, Equity Futures Edge Lower Pre-Bell Wednesday Ahead of Nvidia Earnings
Ocugen Announces Completion of Dosing in Subjects With Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy